| Status | In progress |
| Process | STA 2018 |
| ID number | 1427 |
Provisional Schedule
| Committee meeting: 1 | 07 September 2021 |
| Expected publication | 17 November 2021 |
Project Team
| Project lead | Thomas Feist |
Email enquiries
- If you have any queries please email TACommA@nice.org.uk
| Evidence Review Group / Assessment Group | Kleijnen Systematic Reviews Ltd |
Consultees
| Companies sponsors | BeiGene |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Lymphoma Action |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists |
Commentators
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 February 2021 | The timelines for this appraisal have been revised and the first appraisal committee meeting is now scheduled to take place on 7 September 2021. This is to allow the company to address the decision problem in the final scope in its submission. |
| 27 October 2020 | Invitation to participate |
| 23 July 2020 - 20 August 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 31 July 2017 | In progress. DHSC referral received |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance